)
Clinuvel Pharmaceuticals (CUV) investor relations material
Clinuvel Pharmaceuticals H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Revenue grew 4% year-over-year to $36.93 million for the half year ended 31 December 2025, marking a record first-half result and the 20th consecutive profitable period.
Profit after tax was $10.44 million, down 26% year-over-year, reflecting increased investment in R&D and business expansion.
Cash reserves rose 4% to $233 million, supporting self-funded growth, ongoing operations, and future initiatives.
The company remains debt-free for 21 years, with no equity dilution since 2016 and a self-financed expansion strategy.
EMA approved year-round SCENESSE® treatment for EPP, and an ADR Level II uplisting to Nasdaq is underway.
Financial highlights
Total expenses rose 22% to $25.98 million, mainly due to higher R&D, personnel, clinical, commercial, and corporate costs.
Interest income increased 14% to $5.3 million, driven by higher cash balances and favorable term deposit rates.
Other income saw a negative swing of $4.6 million due to unrealized FX translation losses.
Dividend of 5.0 cents per share fully franked was paid in September 2025.
Net assets increased to just under $250 million, with net tangible asset backing per ordinary security at $4.93.
Outlook and guidance
Sufficient funds to run programs through 2028, with continued investment in R&D, manufacturing, and commercial expansion.
Anticipates topline results for CUV105 vitiligo study and start of CUV107 in H2 2026, plus preclinical readout for new controlled-release formulation in H1 2026.
Uplisting to Nasdaq and expanded commercial activities planned, with higher second-half revenues expected due to seasonal demand.
Key regulatory milestones expected in 2026, including EMA engagement for adolescent EPP and Health Canada decision.
Next Clinuvel Pharmaceuticals earnings date
Next Clinuvel Pharmaceuticals earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)